Startup Showcase: Rejuvenate Biomed: What do you think?

Rejuvenate Biomed are ready to take their first Longevity therapy into clinical trials: Invest, buy, or both?

It’s time to have your say on Rejuvenate Biomed.

We like Longevity therapies derived from existing ‘off-patent’ drugs and this is what Rejuvenate Biomed are doing; they’re de-risked, unencumbered by licensing complexities and have great results from their research … but that’s just our opinion – you’re the ones with the investment and buying potential: What do you think?

  • Watch the video pitch and investor questions;
  • Check-out the slide deck;
  • Take the 30 secs survey and see what others think!

The video pitch and investor questions:

The slide deck:

Rejuvenate Biomed Pitch Deck Longevity.Technology

The 30-second survey (with live results):

Would you like to know more?

We’re happy to pass along your comments and questions to the Rejuvenate Biomed team: you can email us via this link. Thanks.


Thanks for engaging – we have regular Startup Showcases coming-up: stay tuned!

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Latest articles

Epigenetic regulation of protein homeostasis following DNA damage

Recent study identifies critical regulator of protein biosynthesis recovery and homeostasis required for Longevity. Unresolved DNA damage caused by intrinsic and environmental factors accumulates during...

Deliver us from aging – the Quicksilver method

Bigger certainly doesn't mean better when it comes to Quicksilver's nutraceutical delivery methods. The COVID-19 pandemic has caused an upturn in the supplements industry; from...

Deep Longevity and Longenesis collaborate to clock aging

Start the clock to stop the clock – centralised data will aid Longevity research.  Deep Longevity, which engages in the development of explainable AI systems...

Big Brother approach to accelerate preclinical studies develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...